Advertisement

Sponsored by Merck

Help protect
against
pediatric
invasive
pneumococcal
disease (IPD)

Advertisement

Sponsored by Merck

VAXNEUVANCE is indicated
for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3,
4, 5, 6A, 6B, 7F, 9V, 14, 18C,
19A, 19F, 22F, 23F, and 33F
in individuals 6 weeks of age
and older.

 VAXNEUVANCE  provides robust   immunogenicity,   including coverage for    key disease-causing      serotypes 3, 22F,  
and 33F1,2,a

aAt 30 days post dose 4, GMC ratios vs PCV13 were comparable for 13 shared serotypes, superior for shared serotype 3 (1.43; 95% CI: 1.30, 1.57), and superior for unique serotypes
22F and 33F. Study Design: Double-blind, active comparator-controlled study evaluating VAXNEUVANCE
as a 4-dose series in healthy infants (N=1720) randomized to receive either VAXNEUVANCE or PCV13.
Vaccinate with
VAXNEUVANCE today.
LEARN MORE

SELECT SAFETY INFORMATION

Do not administer VAXNEUVANCE to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.

Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant’s medical status and the potential benefits and possible risks.

The most commonly reported solicited adverse reactions in children vaccinated at 2, 4, 6, and 12 through 15 months of age, provided as a range across the 4-dose series, were: irritability (57.3% to 63.4%), somnolence (24.2% to 47.5%), injection-site pain (25.9% to 40.3%), fever ≥38.0°C (13.3% to 20.4%), decreased appetite (14.1% to 19.0%), injection-site induration (13.2% to 15.4%), injection-site erythema (13.7% to 21.4%), and injection-site swelling (11.3% to 13.4%).

The most commonly reported solicited adverse reactions in children 2 through 17 years of age vaccinated with a single dose were: injection-site pain (54.8%), myalgia (23.7%), injection-site swelling (20.9%), injection-site erythema (19.2%), fatigue (15.8%), headache (11.9%), and injection-site induration (6.8%).

Vaccination with VAXNEUVANCE may not protect all vaccine recipients.

Before administering VAXNEUVANCE, please read the accompanying Prescribing Information. The Patient Information also is available.

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

US-PVC-01482 09/23

Prescribing Information

Patient Information

References

Abbreviations

Sponsored by Merck

Advertisement

Sponsored by Merck

Advertisement